Subtopic Deep Dive
EGFR Mutations in Non-Small Cell Lung Cancer
Research Guide
What is EGFR Mutations in Non-Small Cell Lung Cancer?
EGFR mutations in non-small cell lung cancer (NSCLC) are activating alterations, primarily exon 19 deletions and L858R point mutation, that predict sensitivity to tyrosine kinase inhibitors (TKIs) like gefitinib and osimertinib in 15-40% of adenocarcinoma cases.
These mutations occur more frequently in East Asian populations and nonsmokers. Gefitinib demonstrated superior efficacy over chemotherapy in EGFR-mutated pulmonary adenocarcinoma (Mok et al., 2009, 8148 citations). Osimertinib improved progression-free and overall survival as first-line therapy (Soria et al., 2017, 4982 citations; Ramalingam et al., 2019, 2641 citations).
Why It Matters
EGFR mutations identify patients for targeted TKI therapy, avoiding ineffective chemotherapy and improving survival in advanced NSCLC. Mok et al. (2009) showed gefitinib doubled response rates in mutation-positive East Asian nonsmokers. Soria et al. (2017) established osimertinib as first-line standard, reducing CNS progression. Pao et al. (2005) identified T790M resistance mutations, guiding development of third-generation TKIs like AZD9291 (Jänne et al., 2015). This guides precision oncology, with ethnic prevalence differences informing global screening (Travis et al., 2011).
Key Research Challenges
Acquired TKI Resistance
Secondary T790M mutations emerge in resistant EGFR-mutated NSCLC tumors after gefitinib or erlotinib (Pao et al., 2005, 3509 citations). T790M increases ATP affinity, reducing TKI binding (Yun et al., 2008, 2062 citations). Osimertinib overcomes T790M but new resistances arise (Jänne et al., 2015).
Ethnic Prevalence Variation
EGFR mutations show 30-40% prevalence in East Asians versus 15% in Western NSCLC adenocarcinoma patients (Mok et al., 2009). This affects trial generalizability and screening strategies (Travis et al., 2011, 4761 citations). Co-mutations complicate predictions.
Rare Mutation Sensitivity
Exon 20 insertions and uncommon variants show variable TKI responses unlike classic exon 19/L858R (Hirsch et al., 2016). Clinical guidelines struggle with heterogeneous outcomes (Novello et al., 2016, 2625 citations). Genomic screening scales needed for identification.
Essential Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · 2009 · New England Journal of Medicine · 8.1K citations
Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The presence in the tumor of a mutation o...
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · 2017 · New England Journal of Medicine · 5.0K citations
Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adv...
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis, Élisabeth Brambilla, Masayuki Noguchi et al. · 2011 · Journal of Thoracic Oncology · 4.8K citations
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
William Pao, Vincent A. Miller, Katerina Politi et al. · 2005 · PLoS Medicine · 3.5K citations
In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug. This observation should ...
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · 2016 · The Lancet · 3.3K citations
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard et al. · 2019 · New England Journal of Medicine · 2.6K citations
Among patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI. The s...
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Silvia Novello, Fabrice Barlési, Raffaele Califano et al. · 2016 · Annals of Oncology · 2.6K citations
Reading Guide
Foundational Papers
Start with Mok et al. (2009, 8148 citations) for gefitinib efficacy proof; Pao et al. (2005, 3509 citations) for resistance discovery; Yun et al. (2008, 2062 citations) for T790M mechanism; Travis et al. (2011, 4761 citations) for adenocarcinoma classification context.
Recent Advances
Soria et al. (2017, 4982 citations) for osimertinib first-line; Ramalingam et al. (2019, 2641 citations) for survival update; Jänne et al. (2015, 2078 citations) for T790M-targeted therapy.
Core Methods
EGFR sequencing for mutations; FISH for copy number (Cappuzzo et al., 2005); randomized trials like IPASS/FLAURA for TKI vs chemotherapy; crystallographic studies for resistance (Yun et al., 2008).
How PapersFlow Helps You Research EGFR Mutations in Non-Small Cell Lung Cancer
Discover & Search
Research Agent uses searchPapers with 'EGFR exon 19 deletion NSCLC osimertinib' to retrieve Mok et al. (2009), then citationGraph reveals downstream resistance studies like Pao et al. (2005), and findSimilarPapers expands to ethnic cohorts; exaSearch scans 250M+ OpenAlex papers for rare mutation prevalence.
Analyze & Verify
Analysis Agent applies readPaperContent to Soria et al. (2017) FLAURA trial, verifyResponse with CoVe cross-checks survival stats against Ramalingam et al. (2019), and runPythonAnalysis extracts hazard ratios via pandas for meta-analysis; GRADE grading scores evidence as high for first-line osimertinib.
Synthesize & Write
Synthesis Agent detects gaps in post-osimertinib resistance via contradiction flagging across Jänne et al. (2015) and Yun et al. (2008); Writing Agent uses latexEditText for review drafting, latexSyncCitations integrates 10 key papers, latexCompile generates PDF, and exportMermaid visualizes TKI resistance pathways.
Use Cases
"Extract survival data from FLAURA and IPASS trials for EGFR L858R meta-analysis"
Research Agent → searchPapers 'FLAURA IPASS EGFR' → Analysis Agent → readPaperContent (Soria 2017, Mok 2009) → runPythonAnalysis (pandas HR pooling, matplotlib forest plot) → outputs CSV with pooled hazard ratio 0.68 (95% CI).
"Draft LaTeX review on T790M resistance mechanisms with citations"
Synthesis Agent → gap detection (post-TKI resistance) → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Pao 2005, Yun 2008, Jänne 2015) → latexCompile → outputs compiled PDF review.
"Find code for EGFR mutation prevalence analysis from genomic NSCLC papers"
Research Agent → searchPapers 'EGFR NSCLC genomic screening' → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → outputs R script for TCGA mutation frequency visualization.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers 50+ EGFR TKI papers → citationGraph clusters resistance themes → DeepScan 7-step verifies stats (CoVe on Mok 2009 vs Soria 2017). Theorizer generates hypotheses on rare mutation combinatory therapies from Pao et al. (2005) and Hirsch et al. (2016). Chain-of-Verification reduces errors in prevalence meta-analyses.
Frequently Asked Questions
What defines sensitizing EGFR mutations in NSCLC?
Exon 19 deletions and L858R predict TKI response; identified in 15-40% adenocarcinomas, higher in East Asians (Mok et al., 2009).
What methods confirmed gefitinib superiority?
IPASS trial randomized 1217 patients; EGFR mutation testing via sequencing predicted better outcomes vs chemotherapy (Mok et al., 2009, 8148 citations).
What are key papers on EGFR TKI resistance?
Pao et al. (2005) identified T790M in resistant tumors; Yun et al. (2008) showed ATP affinity mechanism; Jänne et al. (2015) tested osimertinib.
What open problems remain in EGFR NSCLC research?
Overcoming osimertinib resistance, optimizing rare mutation therapies, and addressing ethnic co-mutation differences lack prospective data (Hirsch et al., 2016).
Research Lung Cancer Treatments and Mutations with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching EGFR Mutations in Non-Small Cell Lung Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers